December 24, 2002 |
Genentech Inc. and Xoma Ltd. said they have asked U.S. regulators to approve Raptiva, an experimental treatment for moderate to severe psoriasis. Raptiva, a monoclonal antibody given weekly by injection, reduced psoriasis by at least 75% in some 61% of patients taking it for a year in clinical trials. Biogen Inc. is awaiting approval for its own experimental psoriasis treatment, Amevive. And Johnson & Johnson and Amgen Inc.
September 11, 2002 |
Biosite Inc., maker of medical diagnostic tests, resolved a licensing dispute with partner Xoma Ltd., which had alleged that Biosite infringed patents. The news sent shares of San Diego-based Biosite up 25%, or $5.22, to $25.77 on Nasdaq. Berkeley-based Xoma rose 36 cents to $5.91, also on Nasdaq. Biosite uses technology licensed from Xoma in manufacturing antibodies for tests to detect drug overdoses and heart disease.
June 29, 1999 |
Eye-care-products maker Allergan Inc. said it will pay up to $11 million to license a bacteria-fighting protein from biopharmaceuticals maker Xoma Ltd. for use in a family of eye-infection treatments. Xoma, which is based in Berkeley, said Irvine's Allergan will make a series of licensing payments as development and sales goals are reached. Allergan also will pay development costs for future products and royalties from sales of products containing the anti-bacterial protein, which Xoma will manufacture for Allergan.
October 29, 1991 |
Xoma Patent Upheld: Xoma Corp., a Berkeley biotechnology company, said a U.S. District Court in San Francisco upheld the validity of its patent covering the use of a genetically engineered treatment for septic shock syndrome, a bacterial infection that kills about 70,000 people in the United States annually. In April, 1990, after being granted a U.S. patent for the treatment, Xoma sued Centocor, a rival, alleging that the Malvern, Pa., company was copying its invention.